Log In
Print
BCIQ
Print
Print this Print this
 

RI-002

  Manage Alerts
Collapse Summary General Information
Company ADMA Biologics Inc.
DescriptionHuman plasma-derived, polyclonal, IV Ig that has standardized high levels of antibodies against respiratory syncytial virus (RSV)
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationPrimary immunodeficiency disease (PIDD)
Indication DetailsTreat primary immunodeficiency disease (PIDD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today